U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07299253) titled 'Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06' on Nov. 26.
Brief Summary: This study aims to systematically evaluate the safety, biodistribution, dosimetry, and preliminary therapeutic potential of [177Lu]Lu-TEFAPI-06 through an exploratory first-in-human (FIH) trial.
Study Start Date: Aug. 16, 2023
Study Type: INTERVENTIONAL
Condition:
Metastatic Solid Tumors (Any Localization)
Intervention:
DRUG: radionuclide therapy with [177Lu]Lu--TEFAPI-06
A Novel Albumin-Binding FAPI Radiopharmaceutical for Theranostics
Recruitment Status: COMPLETED
Sponsor: Lanzhou University Second Hospi...